

Challenges of Convalescent Plasma Infusion Therapy in Coronavirus Infection: A Single Centre Experience

Antiviral Therapy

23, 617-622

DOI: [10.3851/imp3243](https://doi.org/10.3851/imp3243)

Citation Report

#	ARTICLE	IF	CITATIONS
1	MERS: Progress on the global response, remaining challenges and the way forward. <i>Antiviral Research</i> , 2018, 159, 35-44.	1.9	45
2	Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain. <i>Viruses</i> , 2019, 11, 60.	1.5	97
3	Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals. <i>MBio</i> , 2020, 11, .	1.8	186
4	Potential Therapeutic Options for COVID-19. <i>Infectious Microbes & Diseases</i> , 2020, 2, 89-95.	0.5	0
5	Convalescent plasma therapy: a promising coronavirus disease 2019 treatment strategy. <i>Open Biology</i> , 2020, 10, 200174.	1.5	15
6	Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena. <i>Frontiers in Pharmacology</i> , 2020, 11, 585888.	1.6	11
7	Convalescent Blood Products in COVID-19: A Narrative Review. <i>Therapeutic Advances in Infectious Disease</i> , 2020, 7, 204993612096064.	1.1	3
8	The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 219.	7.1	37
9	Innate immune-mediated antiviral response to SARS-CoV-2 and convalescent sera a potential prophylactic and therapeutic agent to tackle COVID-19. <i>Antibody Therapeutics</i> , 2020, 3, 212-220.	1.2	2
10	Immune response in COVID-19: A review. <i>Journal of Infection and Public Health</i> , 2020, 13, 1619-1629.	1.9	281
11	<p>Convalescent Plasma Therapy: An Effective Therapeutic Option to Treat COVID-19? A Narrative Review</p>. <i>International Journal of Clinical Transfusion Medicine</i> , 2020, Volume 8, 7-21.	0.8	4
12	Convalescent Plasma “ Is it Useful for Treating SARS Co-V2 infection?. <i>Indian Journal of Medical Microbiology</i> , 2020, 38, 252-260.	0.3	7
13	Clinical Characteristics, Diagnosis, and Treatment of Major Coronavirus Outbreaks. <i>Frontiers in Medicine</i> , 2020, 7, 581521.	1.2	42
14	COVID-19: The Immune Responses and Clinical Therapy Candidates. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5559.	1.8	25
15	Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments. <i>International Immunopharmacology</i> , 2020, 88, 106885.	1.7	30
16	Treatment of COVID-19: Perspective on Convalescent Plasma Transfusion. <i>Frontiers in Medicine</i> , 2020, 7, 435.	1.2	7
17	Emerging Therapeutic Modalities against COVID-19. <i>Pharmaceuticals</i> , 2020, 13, 188.	1.7	24
18	Potential strategies for combating COVID-19. <i>Archives of Virology</i> , 2020, 165, 2419-2438.	0.9	12

#	ARTICLE	IF	CITATIONS
19	A perspective on potential antibody-dependent enhancement of SARS-CoV-2. <i>Nature</i> , 2020, 584, 353-363.	13.7	413
20	An overview of key potential therapeutic strategies for combat in the COVID-19 battle. <i>RSC Advances</i> , 2020, 10, 28243-28266.	1.7	34
21	Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. <i>Clinical Infectious Diseases</i> , 2021, 73, e531-e539.	2.9	177
22	The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 1991.	2.2	124
23	Neutralizing Antibody Production in Asymptomatic and Mild COVID-19 Patients, in Comparison with Pneumonic COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 2268.	1.0	106
24	Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease. <i>Seminars in Hematology</i> , 2020, 57, 73-82.	1.8	15
25	ADRS due to COVID-19 in midterm pregnancy: successful management with plasma transfusion and corticosteroids. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 3040-3043.	0.7	18
26	Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality. <i>American Journal of Pathology</i> , 2020, 190, 2290-2303.	1.9	197
27	Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1436-1446.	2.8	69
28	Convalescent Plasma Therapy for COVID-19: State of the Art. <i>Clinical Microbiology Reviews</i> , 2020, 33, .	5.7	94
29	SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment. <i>Frontiers in Immunology</i> , 2020, 11, 570927.	2.2	28
30	A 21st Century Evil: Immunopathology and New Therapies of COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 562264.	2.2	8
31	Case Report: Convalescent Plasma, a Targeted Therapy for Patients with CVID and Severe COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 596761.	2.2	45
32	COVID-19: an update on diagnostic and therapeutic approaches. <i>BMB Reports</i> , 2020, 53, 191-205.	1.1	72
33	Immune responses during COVID-19 infection. <i>Oncolmmunology</i> , 2020, 9, 1807836.	2.1	103
34	Risk-benefit analysis on the clinical significance of convalescent plasma therapy in the management of COVID-19. <i>Postgraduate Medical Journal</i> , 2021, 97, 467-468.	0.9	4
35	Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?. <i>Frontiers in Microbiology</i> , 2020, 11, 1818.	1.5	81
36	Convalescent Plasma: A Potential Life-Saving Therapy for Coronavirus Disease 2019 (COVID-19). <i>Frontiers in Public Health</i> , 2020, 8, 437.	1.3	12

#	ARTICLE	IF	CITATIONS
37	Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. <i>Nature Microbiology</i> , 2020, 5, 1185-1191.	5.9	553
38	Sustained Responses of Neutralizing Antibodies Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Recovered Patients and Their Therapeutic Applicability. <i>Clinical Infectious Diseases</i> , 2021, 73, e550-e558.	2.9	14
39	Convalescent plasma therapy in critically ill coronavirus disease 2019 patients with persistently positive nucleic acid test, case series report. <i>Medicine (United States)</i> , 2020, 99, e21596.	0.4	12
40	Multidisciplinary Guidance Regarding the Use of Immunomodulatory Therapies for Acute Coronavirus Disease 2019 in Pediatric Patients. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 716-737.	0.6	40
41	COVID-19 Therapeutic Options Under Investigation. <i>Frontiers in Pharmacology</i> , 2020, 11, 1196.	1.6	65
42	A case of COVID-19 Convalescent Plasma Donation in Greece: Directed donation for compassionate use in the donor's critically ill father. <i>Transfusion Clinique Et Biologique</i> , 2020, 27, 269-270.	0.2	6
43	COVID-19 therapy with mesenchymal stromal cells (MSC) and convalescent plasma must consider exosome involvement: Do the exosomes in convalescent plasma antagonize the weak immune antibodies?. <i>Journal of Extracellular Vesicles</i> , 2020, 10, e12004.	5.5	43
44	Convalescent Plasma Therapy for COVID-19: Current Status and Future Directions. <i>Journal of Neuroanaesthesiology and Critical Care</i> , 2020, 7, 140-147.	0.1	1
45	Antibody Binding to SARS-CoV-2 S Glycoprotein Correlates with but Does Not Predict Neutralization. <i>Viruses</i> , 2020, 12, 1214.	1.5	26
46	COVID-19: the epidemiology and treatment. <i>British Journal of Hospital Medicine (London, England:)</i> Tj ETQq1 1 0.784314 rgBT /Overl	0.2	9
47	COVID-19 as an Acute Inflammatory Disease. <i>Journal of Immunology</i> , 2020, 205, 12-19.	0.4	133
48	Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design. <i>Transfusion</i> , 2020, 60, 1123-1127.	0.8	37
49	Convalescent plasma in Covid-19: Possible mechanisms of action. <i>Autoimmunity Reviews</i> , 2020, 19, 102554.	2.5	401
50	An Update on Current Therapeutic Drugs Treating COVID-19. <i>Current Pharmacology Reports</i> , 2020, 6, 56-70.	1.5	438
51	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions. <i>Viruses</i> , 2020, 12, 526.	1.5	197
52	Molecular Targets in the Chemotherapy of Coronavirus Infection. <i>Biochemistry (Moscow)</i> , 2020, 85, 523-530.	0.7	10
53	Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 796-803.	1.5	9
54	Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. <i>Science</i> , 2020, 369, 643-650.	6.0	1,104

#	ARTICLE	IF	CITATIONS
55	Current treatment approaches for COVID-19 and the clinical value of transfusion-related technologies. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102839.	0.5	16
56	Antibody Dependent Enhancement Due to Original Antigenic Sin and the Development of SARS. <i>Frontiers in Immunology</i> , 2020, 11, 1120.	2.2	53
57	Early experience with convalescent plasma as immunotherapy for COVID-19 in China: Knowns and unknowns. <i>Vox Sanguinis</i> , 2020, 115, 507-514.	0.7	30
58	Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106054.	1.1	410
59	Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United States. <i>Transfusion</i> , 2020, 60, 1024-1031.	0.8	32
60	The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses. <i>Frontiers in Microbiology</i> , 2020, 11, 658.	1.5	86
61	Effectiveness of convalescent plasma therapy in severe COVID-19 patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 9490-9496.	3.3	1,601
62	Middle East respiratory syndrome. <i>Lancet, The</i> , 2020, 395, 1063-1077.	6.3	358
63	Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks. <i>Pathogens</i> , 2020, 9, 186.	1.2	434
64	A potentially effective treatment for COVID-19: A systematic review and meta-analysis of convalescent plasma therapy in treating severe infectious disease. <i>International Journal of Infectious Diseases</i> , 2020, 98, 334-346.	1.5	58
65	Safety of Plasma Infusions in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1905-1913.	2.2	8
66	Pandemic COVID-19: Current status and challenges of antiviral therapies. <i>Genes and Diseases</i> , 2020, 7, 502-519.	1.5	11
67	Convalescent plasma therapy in patients with COVID-19. <i>Journal of Clinical Apheresis</i> , 2020, 35, 367-373.	0.7	29
68	Severe refractory COVID-19 patients responding to convalescent plasma; A case series. <i>Annals of Medicine and Surgery</i> , 2020, 56, 125-127.	0.5	41
69	Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102867.	0.5	50
70	The Emerging Role of Convalescent Plasma in the Treatment of COVID-19. <i>HemaSphere</i> , 2020, 4, e409.	1.2	42
71	Antibody therapies for the treatment of COVID-19. <i>Antibody Therapeutics</i> , 2020, 3, 101-108.	1.2	10
72	Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients. <i>Cell Reports Medicine</i> , 2020, 1, 100016.	3.3	102

#	ARTICLE	IF	CITATIONS
73	Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19. International Journal of Risk and Safety in Medicine, 2020, 31, 47-51.	0.3	29
74	Treatment for emerging viruses: Convalescent plasma and COVID-19. Transfusion and Apheresis Science, 2020, 59, 102790.	0.5	135
75	Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic. Transfusion Medicine Reviews, 2020, 34, 145-150.	0.9	68
76	The impact of the SARS-CoV-2 infection, with special reference to the hematological setting. Journal of Medical Virology, 2021, 93, 223-233.	2.5	23
77	Battle against COVID-19: Efficacy of Convalescent Plasma as an emergency therapy. American Journal of Emergency Medicine, 2021, 41, 244-246.	0.7	11
78	Clinical application of rapid diagnostic test kit for SARS-CoV-2 antibodies into the field of patient care. Journal of Microbiology, Immunology and Infection, 2021, 54, 97-100.	1.5	15
79	Clinical trial protocols of repurposed prophylaxis for COVID-19: A review. Infectious Diseases Now, 2021, 51, 7-13.	0.7	5
80	Characterization of 100 sequential SARS-CoV-2 convalescent plasma donations. Transfusion, 2021, 61, 12-16.	0.8	28
81	Evolutionary artificial intelligence based peptide discoveries for effective Covid-19 therapeutics. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 165978.	1.8	22
82	Convalescent plasma therapy in patients with COVID-19. Transfusion and Apheresis Science, 2021, 60, 102955.	0.5	52
83	SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: Future predictions. Biomedical Journal, 2021, 44, 86-93.	1.4	34
84	Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma. Journal of Virological Methods, 2021, 288, 114031.	1.0	75
85	COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study. International Journal of Infectious Diseases, 2021, 103, 439-446.	1.5	39
86	Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel. Annals of Internal Medicine, 2021, 174, 93-95.	2.0	38
87	Exploring the multifocal therapeutic approaches in COVID-19: A ray of hope. International Immunopharmacology, 2021, 90, 107156.	1.7	5
88	Convalescent plasma may be a possible treatment for COVID-19: A systematic review. International Immunopharmacology, 2021, 91, 107262.	1.7	37
89	Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of <i>in vitro</i> , <i>in vivo</i> , and clinical trials. Theranostics, 2021, 11, 1207-1231.	4.6	24
90	COVID-19. Critical Care Nursing Quarterly, 2021, 44, 128-137.	0.4	17

#	ARTICLE	IF	CITATIONS
91	Successful recovery from COVID-19 in three kidney transplant recipients who received convalescent plasma therapy. <i>Transplant Infectious Disease</i> , 2021, 23, e13451.	0.7	30
92	Use of convalescent plasma for COVID-19 in India: A review & practical guidelines. <i>Indian Journal of Medical Research</i> , 2021, 153, 64.	0.4	5
93	Middle East respiratory syndrome coronavirus infection profile in Qatar: An 8-year experience. <i>IDCases</i> , 2021, 24, e01161.	0.4	5
94	Potential Therapeutic Approaches for SARS CoV2 Infection. <i>SpringerBriefs in Applied Sciences and Technology</i> , 2021, , 71-114.	0.2	0
95	Presence and short-term persistence of SARS-CoV-2 neutralizing antibodies in COVID-19 convalescent plasma donors. <i>Transfusion</i> , 2021, 61, 1148-1159.	0.8	11
96	Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. <i>Frontiers in Physiology</i> , 2021, 12, 593223.	1.3	113
97	Perspective on therapeutic and diagnostic potential of camel nanobodies for coronavirus disease-19 (COVID-19). <i>3 Biotech</i> , 2021, 11, 89.	1.1	29
98	Therapeutic Strategies in the Management of COVID-19. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 636738.	1.6	10
99	Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID-19) treatment: A systematic review and meta-analysis based on recent studies and previous respiratory pandemics. <i>Reviews in Medical Virology</i> , 2021, 31, e2225.	3.9	17
100	Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis. <i>F1000Research</i> , 2021, 10, 64.	0.8	5
101	Selecting COVID-19 convalescent plasma for neutralizing antibody potency using a high-capacity SARS-CoV-2 antibody assay. <i>Transfusion</i> , 2021, 61, 1160-1170.	0.8	18
102	Convalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID-19. <i>Clinical Microbiology Newsletter</i> , 2021, 43, 23-32.	0.4	29
104	Perspectives for immune plasma treatment of COVID-19. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 1-9.	0.4	4
105	COVID-19: Immunology, Immunopathogenesis and Potential Therapies. <i>International Reviews of Immunology</i> , 2022, 41, 171-206.	1.5	30
106	Retrospective analysis of 426 donors of a convalescent collective after mild COVID-19. <i>PLoS ONE</i> , 2021, 16, e0247665.	1.1	5
107	Prevalence of Foreign Body Aspiration in Children in a Tertiary Care Hospital. <i>Journal of the Nepal Medical Association</i> , 2021, 59, 111-115.	0.1	3
108	Factors driving availability of COVID-19 convalescent plasma: Insights from a demand, production, and supply model. <i>Transfusion</i> , 2021, 61, 1370-1376.	0.8	2
109	Efficacy of convalescent plasma according to blood groups in COVID-19 patients. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 45-48.	0.4	4

#	ARTICLE	IF	CITATIONS
110	COVID-19 Pandemic: Advances in Diagnosis, Treatment, Organoid Applications and Impacts on Cancer Patient Management. <i>Frontiers in Medicine</i> , 2021, 8, 606755.	1.2	4
111	Evaluation of six anti-SARS-CoV-2 antibody test kits and practical approaches to optimize the diagnostic performance. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 983-986.	1.5	6
112	Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis. <i>F1000Research</i> , 0, 10, 64.	0.8	2
113	Nicotinic cholinergic system and COVID-19: In silico identification of interactions between $\alpha 7$ nicotinic acetylcholine receptor and the cryptic epitopes of SARS-Co-V and SARS-CoV-2 Spike glycoproteins. <i>Food and Chemical Toxicology</i> , 2021, 149, 112009.	1.8	46
114	A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2. <i>Frontiers in Immunology</i> , 2021, 12, 653189.	2.2	20
115	Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma. <i>Transfusion</i> , 2021, 61, 1705-1709.	0.8	41
116	SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface. <i>Nature Communications</i> , 2021, 12, 1577.	5.8	73
118	Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial. <i>PLoS Medicine</i> , 2021, 18, e1003415.	3.9	72
119	Modelling the impact of plasma therapy and immunotherapy for recovery of COVID-19 infected individuals. <i>Sao Paulo Journal of Mathematical Sciences</i> , 2021, 15, 344-364.	0.2	0
120	Neutralizing monoclonal antibodies for treatment of COVID-19. <i>Nature Reviews Immunology</i> , 2021, 21, 382-393.	10.6	568
121	Convalescent Plasma: An Evidence-Based Old Therapy to Treat Novel Coronavirus Patients. , 0, , .		2
122	Preservation of neutralizing antibody function in COVID-19 convalescent plasma treated using a riboflavin and ultraviolet light-based pathogen reduction technology. <i>Vox Sanguinis</i> , 2021, 116, 1076-1083.	0.7	11
123	Convalescent plasma therapy - a silver lining for COVID-19 management?. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, 43, 201-211.	0.1	3
124	COVID-19 and ARDS: Update on Preventive and Therapeutic Venues. <i>Current Molecular Medicine</i> , 2022, 22, 312-324.	0.6	5
125	Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testing. <i>Heliyon</i> , 2021, 7, e06836.	1.4	11
126	Risk factors for COVID-19 mortality: The effect of convalescent plasma administration. <i>PLoS ONE</i> , 2021, 16, e0250386.	1.1	12
127	The Progress and Challenges of Convalescent Plasma Therapy for Coronavirus Disease 2019. <i>Infectious Diseases & Immunity</i> , 2021, 1, 52-58.	0.2	0
128	Drugs intervention study in COVID-19 management. <i>Drug Metabolism and Personalized Therapy</i> , 2021, , .	0.3	7

#	ARTICLE	IF	CITATIONS
129	Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-20.	1.4	18
130	Convalescent Plasma Immunotherapy - A Possible Mitigation Strategy for SARS-CoV-2 Pandemic. , 0, , .		0
131	Modeling within-Host SARS-CoV-2 Infection Dynamics and Potential Treatments. <i>Viruses</i> , 2021, 13, 1141.	1.5	48
132	Safety and Efficacy of Convalescent Plasma Therapy for the Management of COVID-19: A Systematic Review. <i>Coronaviruses</i> , 2021, 2, .	0.2	0
133	The Convalescent Plasma Craze! Where Does India Stand?. <i>Journal of Laboratory Physicians</i> , 2021, 13, 183-191.	0.4	0
134	Coronavirus Disease 2019 (COVID-19): Current Situation and Therapeutic Options. <i>Coronaviruses</i> , 2021, 2, 481-491.	0.2	17
135	Insights into SARS-CoV-2 evolution, potential antivirals, and vaccines. <i>Virology</i> , 2021, 558, 1-12.	1.1	17
136	Middle East Respiratory Syndrome (MERS) Virusâ€™ Pathophysiological Axis and the Current Treatment Strategies. <i>AAPS PharmSciTech</i> , 2021, 22, 173.	1.5	17
137	COVID-19 convalescent plasma: mechanisms of action and rationale for use: a narrative review. <i>Annals of Blood</i> , 0, 6, 16-16.	0.4	1
138	Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. <i>Frontiers in Medicine</i> , 2021, 8, 684151.	1.2	50
139	Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis. <i>F1000Research</i> , 2021, 10, 64.	0.8	7
140	Convalescent plasma therapy for managing infectious diseases: a narrative review. <i>Annals of Blood</i> , 0, 6, 17-17.	0.4	4
141	Longevity of seropositivity and neutralizing antibodies in recovered MERS patients: a 5-year follow-up study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 292-296.	2.8	8
142	Recent advances in antibodyâ€based immunotherapy strategies for COVIDâ€™19. <i>Journal of Cellular Biochemistry</i> , 2021, 122, 1389-1412.	1.2	26
143	Convalescent plasma therapy as a conventional trick for treating COVID-19: a systematic review and meta-analysis study. <i>New Microbes and New Infections</i> , 2021, 42, 100901.	0.8	5
144	Pharmacological Treatment for the Management of COVID 19: A Narrative Review. <i>Journal of the Nepal Medical Association</i> , 2021, 59, 614-621.	0.1	3
145	ConsideraÃ§Ãµes sobre interaÃ§Ãµes entre medicamentos usados no tratamento de linfomas e na terapia experimental da COVID-19. <i>Research, Society and Development</i> , 2021, 10, e18910917962.	0.0	0
146	Convalescent Plasma Reduces Endogenous Antibody Response in COVID-19: A Retrospective Cross-Sectional Study. <i>Turkish Journal of Haematology</i> , 2021, 38, 321-324.	0.2	1

#	ARTICLE	IF	CITATIONS
147	Characterization of an Anti-Ebola virus Hyperimmune Globulin Derived from Convalescent Plasma. <i>Journal of Infectious Diseases</i> , 2021, , .	1.9	3
148	Convalescent plasma therapy: A promising solution for SARS-CoV-2 outbreak. <i>Journal of Cellular Biotechnology</i> , 2021, 7, 11-17.	0.1	1
149	Efficacy and harms of convalescent plasma for treatment of hospitalized COVID-19 patients: a systematic review and meta-analysis. <i>Archives of Medical Science</i> , 2021, 17, 1251-1261.	0.4	6
150	Herramientas biotecnológicas en el diagnóstico, prevención y tratamiento frente a pandemias. <i>Revista Bionatura</i> , 2021, 3, 2091-2113.	0.1	0
151	Usefulness of convalescent plasma transfusion for the treatment of severely ill COVID-19 patients in Pakistan. <i>BMC Infectious Diseases</i> , 2021, 21, 1014.	1.3	7
153	Detection of SARS-CoV-2 independent immunoregulatory activity of COVID-19 convalescent plasma. <i>Transfusion</i> , 2021, 61, 3087-3093.	0.8	2
154	Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
155	Prevention of COVID-19: Preventive Strategies for General Population, Healthcare Setting, and Various Professions. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1318, 575-604.	0.8	0
156	MERS-CoV: epidemiology, molecular dynamics, therapeutics, and future challenges. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2021, 20, 8.	1.7	22
157	Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses. <i>Frontiers in Immunology</i> , 2020, 11, 628971.	2.2	51
171	Convalescent Plasma Therapy: A New Flair of Hope in the Fight Against the Novel Corona Virus Pandemic (COVID-19). <i>Nano LIFE</i> , 2021, 11, 2050004.	0.6	1
172	Convalescent Plasma: A Challenging Tool to Treat COVID-19 Patients—A Lesson from the Past and New Perspectives. <i>BioMed Research International</i> , 2020, 2020, 1-8.	0.9	19
173	The convalescent sera option for containing COVID-19. <i>Journal of Clinical Investigation</i> , 2020, 130, 1545-1548.	3.9	775
174	Deployment of convalescent plasma for the prevention and treatment of COVID-19. <i>Journal of Clinical Investigation</i> , 2020, 130, 2757-2765.	3.9	649
175	Effectiveness of Convalescent Plasma Therapy for COVID-19 Patients in Hunan, China. <i>Dose-Response</i> , 2020, 18, 155932582097992.	0.7	11
176	Convalescent Plasma for COVID-19: An Old Therapy for a Novel Pathogen. , 2020, 17, .		2
177	Management of critically ill patients with COVID-19 in ICU: statement from front-line intensive care experts in Wuhan, China. <i>Annals of Intensive Care</i> , 2020, 10, 73.	2.2	151
178	Drug Repurposing for Prevention and Treatment of COVID-19: A Clinical Landscape. <i>Discoveries</i> , 2020, 8, e121.	1.5	15

#	ARTICLE	IF	CITATIONS
179	Convalescent Plasma in the Treatment of Severe COVID-19: A Systematic Review and Meta-Analysis. Iranian Journal of Public Health, 2020, 49, 2022-2031.	0.3	6
180	Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19. Aging, 2020, 12, 6536-6542.	1.4	117
181	Dynamic monitoring of immune function indexes in COVID-19 patients. Aging, 2020, 12, 24596-24603.	1.4	5
182	Progress in Studies on Structural and Remedial Aspects of Newly Born Coronavirus, SARS-CoV-2. Current Topics in Medicinal Chemistry, 2020, 20, 2362-2378.	1.0	6
183	Current Perspectives of convalescent plasma therapy in COVID-19. Acta Biomedica, 2020, 91, e2020175.	0.2	11
184	Letters to the Editor. Journal of the American Veterinary Medical Association, 2020, 256, 1317-1320.	0.2	2
185	Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea. Journal of Korean Medical Science, 2020, 35, e149.	1.1	283
186	Plant-Based Drugs and Vaccines for COVID-19. Vaccines, 2021, 9, 15.	2.1	34
187	Interim Guidelines on Antiviral Therapy for COVID-19. Infection and Chemotherapy, 2020, 52, 281.	1.0	29
188	Convalescent Plasma Therapy for Coronavirus Disease 2019. Infection and Chemotherapy, 2020, 52, 307.	1.0	10
189	Current status of COVID-19 treatment: An opinion review. World Journal of Virology, 2020, 9, 27-37.	1.3	12
190	Coronavirus disease 2019 (COVID-19): latest developments in potential treatments. Drugs in Context, 2020, 9, 1-14.	1.0	14
191	Genomic diversity and evolution, diagnosis, prevention, and therapeutics of the pandemic COVID-19 disease. PeerJ, 2020, 8, e9689.	0.9	34
192	Immunotherapy in the Treatment of COVID-19. Pediatric Hematology/Oncology and Immunopathology, 2021, 20, 158-168.	0.1	0
193	Current treatment strategies for COVID-19 (Review). Molecular Medicine Reports, 2021, 24, .	1.1	19
194	Personalized therapy: can it tame the COVID-19 monster?. Personalized Medicine, 2021, 18, 583-593.	0.8	4
195	COVID-19 convalescent plasma product: Harvesting plasma from single unit whole blood, a cost effective alternative to plasmapheresis. Global Journal of Transfusion Medicine, 2020, .	0.0	0
196	A SARS-CoV2-jÄrvÄny hatÄsa a hazai vÄrellÄtÄsra. Transfusio, 2020, 53, 96-105.	0.0	5

#	ARTICLE	IF	CITATIONS
199	Re-tasking the use of pre-existing medications and potential therapeutic options for coronavirus disease (COVID-19): systematic review of clinical studies. <i>Drug Discoveries and Therapeutics</i> , 2020, 14, 109-116.	0.6	4
201	Strategies for search of pharmacological drugs against SARS-CoV-2 on the base of studying the structural-genetic features of coronaviruses SARS-CoV, MERS-CoV and SARS-CoV-2. <i>Reviews on Clinical Pharmacology and Drug Therapy</i> , 2020, 18, 269-296.	0.2	2
202	Modeling the Impact of Various Treatment and Prevention Tactics on COVID-19 Worldwide. , 2021, , 195-210.		0
203	the-convalescent-serum-for-treatment-of-covid-19-infection-review. <i>European Journal of Medical and Educational Technologies</i> , 2020, 13, em2005.	0.7	4
204	SARS-CoV-2 Virüsüne Enfekte Kritik Hastaların Tedavisinde Konvelesan (Akımmun) Plazma Kullanımı. <i>Journal of Biotechnology and Strategic Health Research</i> , 0, , .	0.8	1
205	Practical Considerations in Convalescent Plasma Therapy for Coronavirus Disease 2019. <i>The Korean Journal of Blood Transfusion</i> , 2020, 31, 67-69.	0.1	2
206	The importance of determining the amount of therapeutic units before using convalescent plasma. <i>Future Virology</i> , 2021, 16, 791-794.	0.9	0
209	Laboratory Tests for COVID-19: A Review of Peer-Reviewed Publications and Implications for Clinical Use. <i>Missouri Medicine</i> , 2020, 117, 184-195.	0.3	17
210	Therapeutic strategies against COVID-19. <i>Acta Biomedica</i> , 2020, 91, e2020038.	0.2	3
211	A Narrative Review of a Pulmonary Aerosolized Formulation or a Nasal Drop Using Sera Containing Neutralizing Antibodies Collected from COVID-19-Recovered Patients as a Probable Therapy for COVID-19. <i>Iranian Journal of Medical Sciences</i> , 2021, 46, 151-168.	0.3	2
213	Current status of therapeutic approaches and vaccines for SARS-CoV-2. <i>Future Microbiology</i> , 2021, 16, 1319-1326.	1.0	2
214	Treatment of SARS-CoV-2 (COVID-19): A safety perspective. <i>World Journal of Pharmacology</i> , 2021, 10, 1-32.	1.3	1
215	The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines. <i>Biochemical Society Transactions</i> , 2021, 49, 2879-2890.	1.6	16
216	Convalescent plasma therapy in obese severe COVID-19 adolescents: Two cases report. <i>Annals of Medicine and Surgery</i> , 2021, 72, 103084.	0.5	1
217	Convalescent plasma for COVID-19 in the intensive care unit. <i>Anaesthesiology Intensive Therapy</i> , 2021, 53, 398-402.	0.4	2
218	Immune Response in 465 Hematological Patients Vaccinated with mRNA Vaccine Against SARS-CoV-2: A Single Centre Experience. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
219	Booster Vaccination to Reduce SARS-CoV-2 Transmission and Infection. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 327.	3.8	35
220	An Old Therapy, Convalescent Plasma, for Coronavirus Disease-19: Do We Have All the Answer?. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2020, 8, 530-537.	0.1	0

#	ARTICLE	IF	CITATIONS
222	Plasma therapy: a passive resistance against the deadliest. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-10.	1.4	5
223	Convalescent plasma therapy against the emerging SARS-CoV-2 variants: Delineation of the potentialities and risks. <i>International Journal of Surgery</i> , 2022, 97, 106204.	1.1	17
224	Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients. <i>Transfusion and Apheresis Science</i> , 2022, 61, 103355.	0.5	9
225	Insight into COVID-19's epidemiology, pathology, and treatment. <i>Heliyon</i> , 2022, 8, e08799.	1.4	19
226	Safety of convalescent plasma therapy for COVID-19 patients and analysis of viral kinetics: a single-center, open-label, single-arm, interventional study in Japan. <i>GHM Open</i> , 2022, 2, 38-43.	0.1	4
227	ZRC3308 Monoclonal Antibody Cocktail Shows Protective Efficacy in Syrian Hamsters against SARS-CoV-2 Infection. <i>Viruses</i> , 2021, 13, 2424.	1.5	4
228	The Role of Molecular Modeling and Bioinformatics in Treating a Pandemic Disease: The Case of COVID-19. <i>The Open Covid Journal</i> , 2021, 1, 216-234.	0.4	1
229	Rapid Serological Testing for Managing the COVID-19 Pandemic: A Review. <i>Open Biomarkers Journal</i> , 2021, 11, 99-107.	0.1	0
230	Severe Type of COVID-19: Pathogenesis, Warning Indicators and Treatment. <i>Chinese Journal of Integrative Medicine</i> , 2022, 28, 3-11.	0.7	5
231	Convalescent plasma for treatment of COVID-19: study protocol for an open randomised controlled trial in Sweden. <i>BMJ Open</i> , 2021, 11, e048337.	0.8	2
233	Multiple Routes of Antibody-Dependent Enhancement of SARS-CoV-2 Infection. <i>Microbiology Spectrum</i> , 2022, 10, e0155321.	1.2	30
234	Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials. <i>International Immunopharmacology</i> , 2022, 109, 108786.	1.7	7
235	Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 822599.	1.8	28
240	Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial). <i>BMJ Open</i> , 2022, 12, e055189.	0.8	20
242	Convalescent Plasma Therapy, Therapeutic Formulations of Repurposed Drugs in 20th Century Epidemics against COVID-19: A Systematic Review. <i>Pharmaceutics</i> , 2022, 14, 1020.	2.0	9
243	Efficiency and safety of convalescent plasma therapy in patients with COVID-19: a systematic review. <i>Alexander Saltanov Intensive Care Herald</i> , 2022, , 108-120.	0.2	3
244	Reinforcement of the Standard Therapy with Two Infusions of Convalescent Plasma for Patients with COVID-19: A Randomized Clinical Trial. <i>Journal of Clinical Medicine</i> , 2022, 11, 3039.	1.0	4
245	A Multi-Center, Open-Label, Randomized Controlled Trial to Evaluate the Efficacy of Convalescent Plasma Therapy for Coronavirus Disease 2019: A Trial Protocol (COVIPLA-RCT). <i>Life</i> , 2022, 12, 856.	1.1	4

#	ARTICLE	IF	CITATIONS
246	A Transient Effect of Convalescent Plasma Therapy in a Patient with Severe Covonavirus Disease 2019: A Case Report. <i>Infection and Chemotherapy</i> , 0, 54, .	1.0	1
247	The spike glycoprotein of highly pathogenic human coronaviruses: structural insights for understanding infection, evolution and inhibition. <i>FEBS Open Bio</i> , 2022, 12, 1602-1622.	1.0	6
248	A review of mass spectrometryâ€¢based analyses to understand COVIDâ€¢19 convalescent plasma mechanisms of action. <i>Proteomics</i> , 0, , 2200118.	1.3	3
249	Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies. <i>Annals of Hematology</i> , 2022, 101, 2337-2345.	0.8	17
250	Progress in COVID research and developments during pandemic. <i>View</i> , 2022, 3, .	2.7	7
251	Drugs intervention study in COVID-19 management. <i>Drug Metabolism and Drug Interactions</i> , 2021, 36, 87-98.	0.3	1
252	Differential persistence of neutralizing antibody against SARS-CoV-2 in post immunized Bangladeshi population. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
253	COVID-19 Pandemic: A Remedial Measure Through Convalescent Serum. <i>International Journal of Innovations in Science and Technology</i> , 2020, 2, 46-50.	0.1	4
254	Assessing the impetus and impediments to donate coronavirus disease-2019 convalescent plasma: A survey study from a tertiary care Indian blood center. <i>Iraqi Journal of Hematology</i> , 2022, .	0.0	0
256	Applying Machine Learning to Enhance COVID-19 Prediction and Diagnosis of COVID-19 Treatment Using Convalescent Plasma. <i>Smart Innovation, Systems and Technologies</i> , 2023, , 479-489.	0.5	6
257	Use of convalescent plasma therapy in hospitalised adult patients with non-critical COVID-19: a focus on the elderly from Hungary. <i>GeroScience</i> , 0, , .	2.1	1
258	Computed tomography findings and clinical evidence of improvement in coronavirus disease 2019 infection after convalescent plasma therapy in a critically ill patient. <i>Radiology of Infectious Diseases</i> , 2022, 9, 100.	2.4	0
259	Effect of anticovid plasma on COVID-19 among patients in intensive care unit of COVID hospital. , 2022, , 5-10.		0
260	Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. AÂ¢three-arm randomized controlled clinical trial. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	3
261	Coronavirus Pandemics. , 2023, , 143-222.		0
262	Validation of a SARS-CoV-2 Surrogate Virus Neutralization Test in Recovered and Vaccinated Healthcare Workers. <i>Viruses</i> , 2023, 15, 426.	1.5	3
263	Convalescent Plasma Therapy against COVID-19: An update on the changing facets of the ongoing Pandemic. <i>Current Pharmaceutical Biotechnology</i> , 2023, 24, .	0.9	1
264	High-Throughput Neutralization and Serology Assays Reveal Correlated but Highly Variable Humoral Immune Responses in a Large Population of Individuals Infected with SARS-CoV-2 in the US between March and August 2020. <i>MBio</i> , 2023, 14, .	1.8	4

#	ARTICLE	IF	CITATIONS
265	Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review. Journal of Blood Medicine, 0, Volume 14, 159-187.	0.7	2
266	A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452. Vaccine, 2023, 41, 2184-2197.	1.7	7
267	Exploring the Possibility of use of SARS-CoV-2 Antiserum as an Alternative for Plasma Therapy. Coronaviruses, 2023, 04, .	0.2	0
268	Severe COVID-19: Drugs and Clinical Trials. Journal of Clinical Medicine, 2023, 12, 2893.	1.0	0
271	Therapeutic Interventions for COVID-19. , 0, , .		0